- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
MBI spurs review of Nycomed patent
The U.S. Patent Office has granted a petition from Molecular Biosystems of San Diego asking for a review of an ultrasound contrast agent patent issued to Norwegian contrast developer Nycomed. MBI was granted a similar petition in July relating to
The U.S. Patent Office has granted a petition from Molecular Biosystems of San Diego asking for a review of an ultrasound contrast agent patent issued to Norwegian contrast developer Nycomed. MBI was granted a similar petition in July relating to ultrasound contrast patents received by Sonus Pharmaceutical (SCAN 8/6/97).
MBI said it filed the petition in response to Nycomed's assertion that MBI's Optison contrast agent infringes on one of its patents, U.S. patent no. 5,529,766. Nycomed filed patent infringement claims on Sept. 2 against MBI and Mallinckrodt, and in the same action sought to have its patents take priority over those of Sonus (SCAN 9/17/97).
MBI claims that it brought to the patent office's attention certain prior art references that were not included in Nycomed's patent application. MBI believes that the use of perfluorocarbon gases for ultrasound imaging is not patentable because of the prior art references.
MBI and its marketing partner Mallinckrodt also filed litigation in July in U.S. District Court for the District of Columbia, seeking to have the patents of Nycomed, Bracco, ImaRx Pharmaceutical and Du Pont Merck, and Sonus declared invalid.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
